Another combination therapy for type 2 diabetes (T2DM) has entered the US market. On August 27, 2015, the FDA approved Synjardy, a combination of the sodium glucose cotransporter 2 (SGLT2) inhibitor, empagliflozin, and metformin hydrochloride. The new combination therapy was developed by Eli Lilly and Company and Boehringer Ingelheim Pharmaceuticals, who an-nounced the FDA action in a joint statement.
Synjardy is the third therapy that includes empagliflozin. The first such therapy was approved as a monotherapy and is sold as Jardiance. The second, Glyxambi, com-bines the SGLT2 inhibitor with linagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor.
SGLT2 inhibitors blocks the protein responsible for glucose reabsorption in the excretory system; thus, excess glucose is expelled through the urine. In this combination therapy, the SGLT2 inhibitor complements metformin, a longstanding treatment for T2D that lowers glucose production in the liver and its reabsorption in the intestines.
The FDA’s action is based on findings from earlier clinical trials that involved ad-ministration of empagliflozin and metformin in combination, either with or with-out sulfonylurea, to treat T2DM. The drug is currently available in Europe. Reference
US FDA approves Synjardy (empagliflozin/metformin hydrochloride) tablets for adults with type 2 diabetes [press release]. Ridgefield, CT, and Indianapolis, IN: PRNewswire; August 27, 2015. www.prnewswire.com/news-releases/us-fda-approves-synjardy-empaglifloz-inmetformin-hydrochloride-tablets-for-adults-with-type-2-diabetes-300134171.html. Accessed August 31, 2015.
Exploring Pharmaceutical Innovations, Trust, and Access With CVS Health's CMO
July 11th 2024On this episode of Managed Care Cast, we're talking with the chief medical officer of CVS Health about recent pharmaceutical innovations, patient-provider relationships, and strategies to reduce drug costs.
Listen
How Can Employers Leverage the DPP to Improve Diabetes Rates?
February 15th 2022On this episode of Managed Care Cast, Jill Hutt, vice president of member services at the Greater Philadelphia Business Coalition on Health, explains the Coalition’s efforts to reduce diabetes rates through the Diabetes Prevention Program (DPP).
Listen
Quantifying the Altruism Value for a Rare Pediatric Disease: Duchenne Muscular Dystrophy
January 14th 2025Altruism values for treatments of rare, severe pediatric diseases have not been estimated. This study found the altruism value for a hypothetical new Duchenne muscular dystrophy treatment to be $80 per year.
Read More